Key takeaways:
- IOP measurements with Tono-Vera had ‘sturdy correlation and settlement’ with the Ocular Response Analyzer.
- The system is moveable and consists of options to scale back operator errors.
IOP measurements taken with Tono-Vera, a brand new handheld rebound tonometer, carefully align with these taken with the Ocular Response Analyzer, in response to a cross-sectional examine revealed in Journal of Glaucoma.
“The Ocular Response Analyzer (ORA, Reichert Applied sciences) is a noncontact tonometer that estimates IOP by analyzing corneal responses to deformation induced by an air pulse,” Luiz A.F. Beniz, MD, of Bascom Palmer Eye Institute, and colleagues wrote. “The Tono-Vera (Reichert Applied sciences) is a new rebound tonometer that implements vital enhancements to presently obtainable tonometers, together with a proprietary camera-based positioning system that mixes a colour view of the attention with interactive prompts that guarantee correct angulation, distance and centration, decreasing operator-dependent measurement errors.”
IOP measurements taken with Tono-Vera, a handheld rebound tonometer, carefully align with these taken with the Ocular Response Analyzer. Picture: Adobe Inventory
Beniz and colleagues used each instruments a number of occasions on 54 eyes, 50 with glaucoma and 4 regular. The measurements had been performed consecutively on the identical go to by the identical technician.
“Because the measurements on this examine had been acquired with a pre-market uncalibrated model of the system, an preliminary calibration was crucial to permit a significant comparability,” the researchers wrote. “To deal with this, our pattern was cut up on the affected person degree into calibration [46% of eyes] and validation [54% of eyes] teams.”
In keeping with the outcomes, there was “sturdy correlation and settlement” between measurements from the 2 units. The common distinction between them was “near zero” at –0.4 ± 2.5 mm Hg.
Within the validation pattern, 96.5% of the Tono-Vera measurements had been inside 5 mm Hg of the ORA, 79.3% had been inside 3 mm Hg, and 58.6% had been inside 2 mm Hg.
“These outcomes point out that the Tono-Vera could present correct IOP measurements whereas having some great benefits of portability and user-friendly operation,” Beniz and colleagues wrote. “The Tono-Vera represents a promising addition to the arsenal of moveable medical units in a position to measure IOP.”
Perspective
Whereas glaucoma administration know-how has superior considerably, IOP measurement stays central to analysis and remedy. Goldmann applanation tonometry (Haag-Streit) continues to be thought of the gold normal, however different strategies provide sensible advantages. Analysis has proven that even a 1 mm Hg discount in IOP can lower the danger of development by roughly 10%, underscoring the significance of correct measurement.
The Tono-Vera, a rebound tonometer just like iCare, demonstrated comparable efficiency to the ORA on this examine. It could provide sensible benefits, together with ease of use, computerized alignment with the attention and suppleness to evaluate sufferers in varied positions — even these confined to mattress. From a clinical-legal standpoint, Goldmann tonometry must be utilized in glaucoma circumstances (and suspects) at any time when possible. Nonetheless, in lots of real-world conditions, together with these involving mobility-limited sufferers, its use (even with a Perkins tonometer from Haag-Streit) will not be sensible.
In my very own follow, I’ve discovered that some sufferers are extra relaxed with the iCare rebound tonometer than Goldmann. Whereas not a substitute, rebound tonometry clearly has a spot in medical care, particularly when affected person consolation or entry is a consideration.
Mark Eltis, OD, FAAO
Lecturer, College of Waterloo
Non-public follow, Toronto
Member, Optometric Glaucoma Society
Disclosures: Eltis reviews no related monetary disclosures.
Sources/Disclosures
Collapse
Disclosures:
Beniz reviews no related monetary disclosures. Please see the examine for all different authors’ related monetary disclosures.
